Skip to main content

Table 5 Results of univariate and multivariate analysis of factors associated with OS

From: Utility and predictive value of the CRAFITY score in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus tyrosine kinase inhibitors and PD-1 inhibitor

Parameters

Univeriate analysis #

 

Multiveriate analysis

HR

(95%CI)

P Value

HR

(95%CI)

P Value

CRAFITY score

1.736

0.810–3.720

0.156

 

3.429

1.026–11.455

0.045

Age

1.024

0.987–1.062

0.207

 

1.026

0.976–1.079

0.313

Gender

0.569

0.126–2.570

0.464

    

Pathogeny

1.114

0.364–3.411

0.851

    

ECOG score

1.281

0.394–4.165

0.680

    

Child-Pugh class

0.038

0.000-14.200

0.280

 

0.000

0.000-1.475

0.968

ALT

1.011

0.989–1.033

0.336

 

1.005

0.974–1.038

0.736

AST

1.008

0.994–1.022

0.290

 

1.011

0.984–1.038

0.438

PLR

1.003

0.997–1.009

0.332

 

0.996

0.987–1.005

0.405

NLR

0.972

0.788–1.198

0.788

    

Types of TKIs

0.678

0.381–1.208

0.188

 

0.524

0.218–1.258

0.148

TACE sessions

1.161

1.001–1.347

0.049

 

1.244

1.001–1.546

0.048

BCLC stage

1.347

0.539–3.365

0.524

    

Tumor number

1.292

0.794–2.102

0.302

 

0.867

0.469–1.602

0.649

Tumor size

1.559

0.755–3.223

0.230

 

2.844

0.971–8.328

0.056

  1. # variables with P value ≤ 0.4 in the univariate analysis were further included in the multivariate Cox proportional hazards regression model analysis. OS, overall survival; ECOG, Eastern Cooperative Oncology Group ALT, alanine aminotransferase; AST, aspartate aminotransferase; PLR, platelet/lymphocyte ratio; NLR, neutrophil/lymphocyte ratio; TKIs, tyrosine kinase inhibitors; TACE, transarterial chemoembolization; BCLC Barcelona Clinic Liver Cancer
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us